|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0005768,
umls-concept:C0005791,
umls-concept:C0010802,
umls-concept:C0017262,
umls-concept:C0023473,
umls-concept:C0030705,
umls-concept:C0038250,
umls-concept:C0185117,
umls-concept:C0205197,
umls-concept:C0242485,
umls-concept:C0376152,
umls-concept:C0392762,
umls-concept:C0439859,
umls-concept:C0871261,
umls-concept:C1514468,
umls-concept:C1516698,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C1977882,
umls-concept:C2911684,
umls-concept:C2911692
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2008-2-25
|
|
pubmed:abstractText |
Imatinib mesylate is the initial therapy of choice for chronic myeloid leukemia in chronic phase (CML-CP), but in some patients, the disease becomes resistant to imatinib. Autologous stem cell transplantation using cells collected while in complete cytogenetic response (CCyR) may represent a therapeutic option for these patients. We mobilized and collected autologous CD34(+) stem cells from 20 CML-CP patients in CCyR, 19 of whom were taking imatinib, and measured BCR-ABL expression in the apheresis products, blood and bone marrow using real-time quantitative PCR (RQ-PCR). Stem cells were mobilized with G-CSF 10 microg/kg daily for 5 days. In patients whose initial collection was <2x10(6) CD34(+) cells/kg, G-CSF dose was increased to 10 microg/kg twice daily on the second attempt, and imatinib was held for 14 days if a third attempt was necessary. All 20 patients successfully mobilized the target yield of 2 to 5x10(6) CD34(+) cells/kg; 16 reached target yield with the first mobilization. The median number of CD34(+) cells collected was 4.4 (range, 2.0 - 8.4)x10(6)/kg in a median of 3 (range, 2 - 6) apheresis days. Of 17 patients whose stem cell products were evaluable by RQ-PCR, 11 (65%) had >or=1 daily product with undetectable BCR-ABL; 4 of these (24%) had no detectable BCR-ABL in any apheresis products. BCR-ABL expression in apheresis products was correlated with levels of expression in the blood and marrow prior to mobilization. No patient has yet required transplantation. With median follow-up of 18 months, all patients remain in CCyR and 9 of 16 (54%) have undetectable BCR-ABL in the most recent blood and marrow sample.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1029-2403
|
|
pubmed:author |
pubmed-author:ArtzAndrewA,
pubmed-author:ChuangKarenK,
pubmed-author:GodleyLucyL,
pubmed-author:GordonMelinda KMK,
pubmed-author:KarrisonTheodoreT,
pubmed-author:KebriaeiPartowP,
pubmed-author:LarsonRichard ARA,
pubmed-author:McDonnellDianeD,
pubmed-author:MichaelisLauraL,
pubmed-author:OdenikeOlatoyosiO,
pubmed-author:RichElizabethE,
pubmed-author:SherDorieD,
pubmed-author:StockWendyW,
pubmed-author:ThirmanMichael JMJ,
pubmed-author:WickremaAmitthaA,
pubmed-author:ZhangYanmingY,
pubmed-author:van BesienKoenK
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
49
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
531-7
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:18297531-Adolescent,
pubmed-meshheading:18297531-Adult,
pubmed-meshheading:18297531-Aged,
pubmed-meshheading:18297531-Antigens, CD34,
pubmed-meshheading:18297531-Blood Component Removal,
pubmed-meshheading:18297531-Bone Marrow,
pubmed-meshheading:18297531-Cytogenetic Analysis,
pubmed-meshheading:18297531-Female,
pubmed-meshheading:18297531-Fusion Proteins, bcr-abl,
pubmed-meshheading:18297531-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:18297531-Hematopoietic Stem Cell Mobilization,
pubmed-meshheading:18297531-Humans,
pubmed-meshheading:18297531-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:18297531-Male,
pubmed-meshheading:18297531-Middle Aged,
pubmed-meshheading:18297531-Piperazines,
pubmed-meshheading:18297531-Pyrimidines,
pubmed-meshheading:18297531-Recombinant Proteins,
pubmed-meshheading:18297531-Remission Induction,
pubmed-meshheading:18297531-Transplantation, Autologous,
pubmed-meshheading:18297531-Treatment Outcome
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products.
|
|
pubmed:affiliation |
Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
